Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

The U.S. Food and Drug Administration has reportedly targeted a manufacturer of poppers, an inhalant drug that has gained ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 ...

A cornerstone of the immune system is its ability to maintain self-tolerance. This defense network orchestrates effector responses against pathogenic ...